Evidence map›Paper›PMID 27644956›Full record

ArticleZeitschrift fur Rheumatologie2017

[Shared decision making even for complex systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE)?]

M Schneider, H Carnarius, T Schlegl

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. [State of the art: systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

M SchneiderPoliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland. schneiderm@med.uni-duesseldorf.de.
H CarnariusGlaxoSmithKline GmbH & Co KG, Hamburg, Deutschland.
T SchleglK&A BrandResearch, Nürnberg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe treatment of systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) is an enormous challenge for all involved due to the complexity. This study investigated whether shared decision making (SDM) can advantageously be implemented in such a situation.

methodTo answer this question qualitative group surveys were carried out with rheumatologists according to the standardized method of K&P Psychodrama®. A total of 41 German rheumatologists who had been invited by GlaxoSmithKline (GSK) Germany participated in 2 meetings over a complete day in 2012 and 2013 as well as 2 half-day meetings in 2013, which were carried out by K&A BrandResearch.

resultsIn general rheumatologists were appreciative of their discipline because of the broadly spread field of work, the possibility to "tinker" and the increasing spectrum of effective forms of therapy. Negative points were the increasing amount of work, particularly due to increasing bureaucratic processes, demanding and unreasonable patients. These stressful situations were compensated by treatment of indications that can easily be diagnosed and treated; however, this is contrasted by indications which are insufficiently palpable for patients and physicians alike and this includes SLE. Fear is at the forefront of the interaction, initially by the patient and during the course of treatment ultimately by the physician. In this context, a further fear factor between both parties is the medications that are available for other diseases as support for physician and patient. The necessary emotional distancing of the physician is achieved by a switch to the purely professional level. Personal emotions are depressed by avoidance of empathy.

conclusionThe rheumatologists in this study principally showed excellent prerequisites for SDM; however, for illnesses such as SLE there is a clear need for action on the part of physicians before SDM can be advantageous for affected patients.

Indexed as

Decision MakingPhysician-Patient RelationsAutoimmune DiseasesClinical Decision-MakingGermanyHealth Care SurveysHumansPatient ParticipationPractice Patterns, Physicians'RheumatologistsPhysician-patient-interactionShared decision makingSystemic lupus erythematodes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.